Biotie: Selincro (nalmefene) Receives European Marketing Authorization

Biotie: Selincro (nalmefene) Receives European Marketing Authorization 
TURKU, FINLAND -- (Marketwire) -- 02/28/13 --  Biotie today announced
that its partner H.Lundbeck A/S (Lundbeck) has received European
marketing authorization from the European Commission for Selincro
(nalmefene; an opioid system modulator) for the reduction of alcohol
consumption in adult patients with alcohol dependence. The marketing
authorization applies to all 27 European Union member states. 
Timo Veromaa, President and CEO: "This is very good news to the
patients suffering from alcohol dependence and a most significant
milestone for Biotie as a drug development company." 
Lundbeck will provide Selincro as part of a new treatment concept
that includes continuous psychosocial support focused on the
reduction of alcohol consumption and treatment adherence. Subject to
the completion of pricing and reimbursement discussions, Lundbeck
expects to launch Selincro in its first markets in mid-2013. 
Turku, 28 February 2013 
Biotie Therapies Corp.  
Timo Veromaa
 President and CEO 
Distribution:
 NASDAQ OMX Helsinki
Ltd 
Main Media 
ABOUT SELINCRO (nalmefene):  
Selincro is indicated for the reduction of alcohol consumption in
adult patients with alcohol dependence who have a high drinking risk
level ( > 60 g/day for men, > 40 g/day for women) without physical
withdrawal symptoms and who do not require immediate detoxification.
Selincro should be prescribed in conjunction with continuous
psychosocial support focused on treatment adherence and the reduction
of alcohol consumption. Treatment should be initiated only in
patients who continue to have a high drinking risk level two weeks
after an initial assessment. Selincro is to be taken as-needed; that
is, on each day the patient perceives a risk of drinking alcohol, one
tablet should be taken, preferably 1-2 hours prior to the anticipated
time of drinking. 
Biotie has licensed global rights to Selincroto Lundbeck. Under the
terms of the agreement, Biotie is eligible for up to EUR 89 million
in upfront and milestone payments plus royalties on sales of
Selincro. Biotie has previously received EUR 12 million of such
milestone payments from Lundbeck. Further milestone payments are
expected on commercial launch of Selincro and on the product
potentially reaching certain predetermined sales. Lundbeck is
responsible for the registration, manufacturing and marketing of the
product. 
ABOUT BIOTIE  
Biotie is a specialized drug development company focused on the
development of drugs for neurodegenerative and psychiatric disorders
(e.g. Parkinson's disease, Alzheimer's disease and other cognitive
disorders, alcohol and drug dependence (addiction) and post-traumatic
stress disorder), and inflammatory and fibrotic liver disease. The
company has a strong and balanced development portfolio with several
innovative small molecule and biological drug candidates at different
stages of clinical development. Biotie's products address diseases
with high unmet medical need and significant market potential. 
Biotie's most advanced product, Selincro (nalmefene), licensed to H.
Lundbeck A/S, has on 28 February 2013 received European marketing
authorization for the reduction of alcohol consumption in adult
patients with alcohol dependence who have a high level of alcohol
consumption. In addition, Biotie has a strategic collaboration with
UCB Pharma S.A. covering tozadenant which has successfully completed
a Phase 2b study in 420 patients with advanced Parkinson's disease.
Biotie shares are listed on NASDAQ OMX Helsinki Ltd. 
For further information, please contact: 
Timo Veromaa
President and CEO
tel. +358 2274 8900
email: timo.veromaa@biotie.com 
Virve Nurmi
Investor Relations Manager 
tel. +358 2 274 8900
e-mail: virve.nurmi@biotie.com
www.biotie.com